Carsgen's allogeneic cd19/cd20 car-t therapy administers first dose in an investigator-initiated trial

Shanghai , jan. 13, 2025 /prnewswire/ -- carsgen therapeutics holdings limited (stock code: 2171.hk), a company focused on innovative car t-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that kj-c2219, an allogeneic car t-cell therapy targeting cd19/cd20, has administered the first dose to a patient in an investigator-initiated trial (iit). kj-c2219 is developed based on carsgen's thank-u plus platform and is designed for the treatment of hematologic malignancies and autoimmune diseases.
CAR Ratings Summary
CAR Quant Ranking